StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Evofem Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Evofem Biosciences's R&D Expenses for the twelve months ending Dec 31, 2024 was $1.85M. For fiscal 2024 it was $1.85M, down 37.2% from the year before. Over ten years it grew -9.8% a year on average. The highest annual figure on record is $43.42M in fiscal 2018.

Annual r&d expenses

PeriodPeriod endValueChange
FY2024Dec 31, 2024$1.85M-37.2%
FY2023Dec 31, 2023$2.94M-88.3%
FY2022Dec 31, 2022$25.03M-24.4%
FY2021Dec 31, 2021$33.13M+94.3%
FY2020Dec 31, 2020$17.05M-23.3%
FY2019Dec 31, 2019$22.23M-48.8%
FY2018Dec 31, 2018$43.42M+84.4%
FY2017Dec 31, 2017$23.54M+257.8%
FY2016Dec 31, 2016$6.58M-80.9%
FY2015Dec 31, 2015$34.41M+564.9%
FY2014Dec 31, 2014$5.17M-54.8%
FY2013Dec 31, 2013$11.45M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$649.00K+61.4%
Q3 FY2024Sep 30, 2024$332.00K-38.5%
Q2 FY2024Jun 30, 2024$270.00K-84.0%
Q1 FY2024Mar 31, 2024$594.00K-88.6%
Q2 FY2023Jun 30, 2023$402.00K-94.8%
Q1 FY2023Mar 31, 2023$540.00K-94.8%
Q4 FY2022Dec 31, 2022$1.69M-80.5%
Q3 FY2022Sep 30, 2022$5.21M-40.2%
Q2 FY2022Jun 30, 2022$7.74M-9.0%
Q1 FY2022Mar 31, 2022$10.39M+43.1%
Q4 FY2021Dec 31, 2021$8.66M+45.6%
Q3 FY2021Sep 30, 2021$8.70M+106.3%
Q2 FY2021Jun 30, 2021$8.51M+222.2%
Q1 FY2021Mar 31, 2021$7.26M+71.0%
Q4 FY2020Dec 31, 2020$5.95M+73.3%
Q3 FY2020Sep 30, 2020$4.22M-25.5%
Q2 FY2020Jun 30, 2020$2.64M-49.7%
Q1 FY2020Mar 31, 2020$4.25M-46.2%
Q4 FY2019Dec 31, 2019$3.43M-64.9%
Q3 FY2019Sep 30, 2019$5.66M-42.5%
Q2 FY2019Jun 30, 2019$5.25M-55.7%
Q1 FY2019Mar 31, 2019$7.89M-34.0%
Q4 FY2018Dec 31, 2018$9.77M-12.9%
Q3 FY2018Sep 30, 2018$9.85M+57.3%
Q2 FY2018Jun 30, 2018$11.83M+190.2%
Q1 FY2018Mar 31, 2018$11.96M+503.4%
Q4 FY2017Dec 31, 2017$11.22M+1112.2%
Q3 FY2017Sep 30, 2017$6.26M+549.1%
Q2 FY2017Jun 30, 2017$4.08M+185.5%
Q1 FY2017Mar 31, 2017$1.98M–
Q4 FY2016Dec 31, 2016$925.25K–
Q3 FY2016Sep 30, 2016$964.94K–
Q2 FY2016Jun 30, 2016$1.43M–

More Evofem Biosciences figures

See a number that looks wrong?